PM577a Begins First Human In Vivo Prime Editing Study

Company Prime Medicine Event Type First participant dosed Modality In vivo prime editing (LNP-delivered) Asset PM577a Target ATP7B p.H1069Q Disease Area Wilson disease Summary Prime Medicine dosed the first participant in its global Phase 1/2 study of PM577a, an LNP-delivered prime editor designed to correct…